Efficacy of long term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated colonic diverticular disease - Wikidata - awgldk - TriplyDB

Efficacy of long term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated colonic diverticular disease

Efficacy of long term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated colonic diverticular disease

http://www.wikidata.org/entity/Q33787835

about

Prophylactic antibiotics for preventing recurrent symptomatic episodes of acute diverticulitis Recent advances in the treatment of colonic diverticular disease and prevention of acute diverticulitis Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications Non-interventional study evaluating efficacy and tolerability of rifaximin for treatment of uncomplicated diverticular disease.Meta-analysis: long-term therapy with rifaximin in the management of uncomplicated diverticular disease.The effect of cyclic rifaximin therapy on symptoms of diverticular disease from the perspective of the gastroenterology outpatient clinic: a "real-life" study.Italian consensus conference for colonic diverticulosis and diverticular disease.Review article: the pathophysiology and medical management of diverticulosis and diverticular disease of the colon.Rifaximin pharmacology and clinical implications.Fecal microbiome analysis as a diagnostic test for diverticulitis.Pathophysiology and Therapeutic Strategies for Symptomatic Uncomplicated Diverticular Disease of the Colon.High-fibre diet and Lactobacillus paracasei B21060 in symptomatic uncomplicated diverticular disease.Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases New strategies for the management of diverticular disease: insights for the clinician.Review article: Management of diverticulitis.Preventing recurrent acute diverticulitis with pharmacological therapies The role of rifaximin in the treatment and chemoprophylaxis of travelers' diarrhea.Review article: the current and evolving treatment of colonic diverticular disease.Microencapsulated sodium butyrate administered to patients with diverticulosis decreases incidence of diverticulitis--a prospective randomized study.Role of Fiber in Symptomatic Uncomplicated Diverticular Disease: A Systematic Review.Features and management of colonic diverticular disease.Biologic properties and clinical uses of rifaximin.Lifestyle factors and the course of diverticular disease.Rifaximin: recent advances in gastroenterology and hepatology Management of colonic diverticular disease with poorly absorbed antibiotics and other therapies.Rifaximin in the management of colonic diverticular disease.Practice parameters for the treatment of colonic diverticular disease: Italian Society of Colon and Rectal Surgery (SICCR) guidelines.Diverticular disease: A therapeutic overview.The medical and nonoperative treatment of diverticulitis.Mesalazine and rifaximin in symptomatic uncomplicated diverticular disease.

P2860

Q24201705-5F690861-EE8B-46B8-9014-FC4512DC7B87 Q26769903-8DDD2EE7-B736-40E9-98FF-CDD3546E7574 Q26775927-014BFA77-80E1-46A9-8486-60D907411C02 Q33459930-BDAC5B7A-EE98-4697-8406-3C8A428A80B0 Q33834767-C900DDE2-D4CD-4031-ACB4-4983327CA2B9 Q33871732-CF11168F-BE27-4B09-BEEC-3ED4491CE4B8 Q34418890-9DB01B9A-F483-46D5-BEDA-69BCFEF388EC Q34486456-82A6FC78-3202-4696-94BE-4FF19BE22A18 Q34607677-CD49E8A0-D371-4594-B978-070ADCD566B8 Q35181039-17C4B3F7-AE76-4A7B-AF7A-FE7E2098A645 Q35803757-A364E6E7-DD81-4855-A6F9-A337D44DECD3 Q36378802-E076DD99-77BF-4B81-89C4-0C3498F99032 Q36533648-DFE5A0A1-5AD1-4E91-AA66-CEA1453E411B Q36761883-4AF7BDEF-52B9-4E52-BFAD-5E8FBD581536 Q37032726-C6C9B8AE-5FD4-4895-B8B8-6780BD725DD4 Q37253907-94E0E3DE-70FC-49EF-8514-0573DC2810FA Q37412963-11DD899C-2881-4BED-A88C-AE473D51466C Q37528655-F34AF76A-AAC6-4A2D-97BB-4AEFC3FAC525 Q37605593-DDF61532-34A2-41A1-821A-9A9B122F71E4 Q37673269-6D5BE195-B060-43BF-8590-0E2DAEA1FB0D Q37778789-20FB631B-7C19-4607-9E6D-720375ADB366 Q37827877-CCA21CA9-452E-45B8-9990-A2A38E9AD911 Q38008859-889BBA0F-8D6D-43F0-8A96-DC54A48B2F31 Q38074951-B0B49E22-97B3-4DE5-921B-D5AB05A1FA9B Q38633511-B278DA3F-8569-4135-BC0E-680D5286E568 Q39295479-DDAF4C8F-64D6-4D92-B4A2-79AEFA361216 Q40995957-E1AB6A8D-7EF9-4FF0-91F0-27B104F4AB69 Q41875201-3CDA35D2-5F5B-40CB-A399-D98EF0CE84A3 Q42653528-BF5F83A1-50E5-482D-BA39-589C96406212 Q46143446-92568847-D4DF-4A95-A4A4-C14D6AB71C92

P2860

Efficacy of long term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated colonic diverticular disease

http://www.wikidata.org/entity/Q33787835

description

2007 nî lūn-bûn

@nan

2007 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Efficacy of long term cyclic a ...... d colonic diverticular disease

@ast

Efficacy of long term cyclic a ...... d colonic diverticular disease

@en

type

label

Efficacy of long term cyclic a ...... d colonic diverticular disease

@ast

Efficacy of long term cyclic a ...... d colonic diverticular disease

@en

prefLabel

Efficacy of long term cyclic a ...... d colonic diverticular disease

@ast

Efficacy of long term cyclic a ...... d colonic diverticular disease

@en

P1433

Q33787835-1567EC61-DF68-408E-BBD1-9B429AC5D8D9

P1476

Q33787835-D0C5B10F-B228-4F2C-BAB6-2115090BED90

P2093

Q33787835-02544F0D-5FE5-47B7-B507-980F5DA173E6

Q33787835-0700C633-30DC-4BE3-8438-4ACE494FDDBA

Q33787835-096D8477-1D25-4000-A90D-9D54A20DE533

Q33787835-24A18A10-79F9-4639-AEB5-ACB28B75E7F3

Q33787835-5A161C67-3EC5-4F5C-8187-66FF4F642770

Q33787835-736BB24C-857D-4732-8BE6-5650653BFD1F

Q33787835-928B0FE5-52ED-44D9-8DAD-09884CA9B9C1

Q33787835-B48D385D-2880-418B-8D4E-2A45067334B2

P2860

Q33787835-02DEF3D0-E3A3-4397-8625-0469B586C0FA

Q33787835-0ABCD66C-FFCC-4BF1-BC06-3272119DB15D

Q33787835-30D42703-1FD7-457D-90A4-AD68B2190669

Q33787835-3117D825-9A65-4508-8AD8-6CAF10061279

Q33787835-3FC3A04B-504D-4D85-B4A8-27F2DDAD6CAE

Q33787835-4707033D-8369-4F52-B684-B3C6E2B91226

Q33787835-7BE187B0-9240-46B2-8677-1C6BB4556563

Q33787835-858B913B-7698-4D3C-BDAA-9ABF3F44EE0A

Q33787835-8723F5DC-7C84-445C-8E5F-7B989169B2B9

Q33787835-8ACE45FB-286D-4FE7-8540-90DB452ABFB7

P304

Q33787835-3DE86270-40DC-4D9D-A937-93EFD0BC3EA4

P31

Q33787835-E5D98A35-B462-45E6-9E5D-520F3BE1B13C

P356

Q33787835-E999E97A-A6D7-4056-9046-4B03D39C0316

P407

Q33787835-041A1A91-A169-4A11-B044-8BCE965AC991

P433

Q33787835-4296933D-3496-4EE3-8A32-F187F50C4B47

P478

Q33787835-1A28DBFD-6038-43EC-A25B-1E2D4F703B07

P577

Q33787835-0D8012E2-77E0-4E51-BDE7-3C03F5DC2F09

P698

Q33787835-2F763F93-27DB-451C-9F02-C856B65055E5

P921

Q33787835-6635D1D2-D183-4531-9026-5341B94B2C0A

P932

Q33787835-777220A8-FF23-40A7-B248-60D73FE465BD

P356

P1433

World Journal of Gastroenterology

P1476

Efficacy of long term cyclic a ...... d colonic diverticular disease

@en

P2093

Amanda Vestito

http://www.w3.org/2001/XMLSchema#string

Antonio Colecchia

http://www.w3.org/2001/XMLSchema#string

Davide Festi

http://www.w3.org/2001/XMLSchema#string

Enrico Roda

http://www.w3.org/2001/XMLSchema#string

Francesca Pasqui

http://www.w3.org/2001/XMLSchema#string

Francesca Pistoia

http://www.w3.org/2001/XMLSchema#string

Giovanni Brandimarte

http://www.w3.org/2001/XMLSchema#string

Giuseppe Mazzella

http://www.w3.org/2001/XMLSchema#string

P2860

Potential protective mechanisms of wheat bran fiber.

Diagnosis and treatment of diverticular disease: results of a consensus development conference. The Scientific Committee of the European Association for Endoscopic Surgery.

A prospective study of diet and the risk of symptomatic diverticular disease in men.

Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon.

Diverticular disease of the colon in Europe: epidemiology, impact on citizen health and prevention.

Mastocytosis and disorders of mast cell proliferation.

A role for inflammation in irritable bowel syndrome?

Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial.

Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria.

The 5-year natural history of complicated diverticular disease.

P304

264-269

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.V13.I2.264

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2007-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17226906

http://www.w3.org/2001/XMLSchema#string

P921

P932

4065955

http://www.w3.org/2001/XMLSchema#string